Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
NCT05804656
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
300
Enrollment
INDUSTRY
Sponsor class
Conditions
Glabellar Lines
Interventions
DRUG:
CKDB-501A
DRUG:
Botox®
Sponsor
CKD Bio Corporation